NASDAQ Framework: Guardant Health Inc.
1: Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Guidance in Line With Expectations, As Shield and Reveal in Focus for 2024 Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 4 months ago Guardant Health Earnings: Strong Results Lift 2023 Outlook Mildly; Shares Still Undervalued Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 5 months ago View Source2: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. View Source3: Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California. View Source
Guardant Health Inc., based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers a range of innovative products, including Guardant360 LDT for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for targeted therapies, and Guardant OMNI for immuno-oncology research. In recent years, Guardant has expanded its portfolio with the launch of Reveal, a tumor-agnostic molecular residual disease test, and Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant provides research development services such as regulatory approval consultancy and clinical trial referrals 456.
4: Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Guidance in Line With Expectations, As Shield and Reveal in Focus for 2024 Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 4 months ago Guardant Health Earnings: Strong Results Lift 2023 Outlook Mildly; Shares Still Undervalued Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 5 months ago View Source5: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. View Source6: Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California. View Source
UNKNOWN
The provided facts do not specify whether the founders of Guardant Health Inc. are still leading the company or heavily involved in its operations.
The provided facts do not specify whether the founders of Guardant Health Inc. are still leading the company or heavily involved in its operations.
MEDIUM RISK
Guardant Health Inc. has shown promising developments and expansions in its product portfolio, including FDA-approved tests and new launches like Reveal and Shield 789. However, the company is not expected to generate positive cash flows until 2028, indicating a prolonged period before achieving profitability 10. This places Guardant Health in a medium risk category, as it is still in the early stages of market penetration and faces uncertainties regarding payer coverage and guideline inclusion 11.
Guardant Health Inc. has shown promising developments and expansions in its product portfolio, including FDA-approved tests and new launches like Reveal and Shield 789. However, the company is not expected to generate positive cash flows until 2028, indicating a prolonged period before achieving profitability 10. This places Guardant Health in a medium risk category, as it is still in the early stages of market penetration and faces uncertainties regarding payer coverage and guideline inclusion 11.
7: Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Strong Start to the Year; FDA Meeting Up Next Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 2 months ago Guardant Health Earnings: Guidance in Line With Expectations, As Shield and Reveal in Focus for 2024 Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 4 months ago Guardant Health Earnings: Strong Results Lift 2023 Outlook Mildly; Shares Still Undervalued Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. Rating Price Target Morningstar• 5 months ago View Source8: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. View Source9: Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California. View Source10: Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer, or CRC. It launched Reveal, its MRD test, for CRC in 2021 and a lab-developed test, or LDT, version of Shield, its CRC screening test, in 2022. Although these are promising markets with multi-billion-dollar revenue potential, it is still the early days, and considerable uncertainty surrounds the details of payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028, or two years after Shield’s potential inclusion in the U.S. Preventive Services Task Force, or USPSTF, guidelines in 2026. View Source11: Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer, or CRC. It launched Reveal, its MRD test, for CRC in 2021 and a lab-developed test, or LDT, version of Shield, its CRC screening test, in 2022. Although these are promising markets with multi-billion-dollar revenue potential, it is still the early days, and considerable uncertainty surrounds the details of payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028, or two years after Shield’s potential inclusion in the U.S. Preventive Services Task Force, or USPSTF, guidelines in 2026. View Source
12: Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024 Business Wire Jul 24, 2024 8:05pm Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance Business Wire Jul 23, 2024 12:05pm Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors Business Wire Jul 18, 2024 9:00pm Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer Business Wire Jun 4, 2024 12:05pm Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials Business Wire Jun 3, 2024 1:18pm Guardant Health Named to TIME100 Most Influential Companies Business Wire May 31, 2024 12:05pm Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening Business Wire May 30, 2024 12:05pm Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test Global News Select May 23, 2024 11:40pm FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option Business Wire May 23, 2024 11:03pm Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening Business Wire May 23, 2024 11:05am Guardant Health to Participate in Upcoming Investor Conferences Business Wire May 22, 2024 8:05pm Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications Business Wire May 21, 2024 12:05pm Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire May 17, 2024 12:05pm Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week Business Wire May 16, 2024 12:05pm Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Business Wire May 9, 2024 8:05pm Guardant Health to Participate in Upcoming Investor Conferences Business Wire May 7, 2024 8:05pm Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone Business Wire May 7, 2024 12:00pm Guardant Health shares slide as colon cancer test is set for FDA advisory committee review MarketWatch Dec 20, 2023 1:42pm View Source13: Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer View Source
Guardant Health Inc. is strategically expanding its product portfolio and market presence from 2024 through to 2026. The company is focusing on enhancing its existing offerings, such as the Guardant360® test, with significant upgrades to maintain its best-in-class performance 14. Additionally, Guardant has introduced the Guardant360 TissueNext test, which includes nearly 500 biomarkers to identify more treatment options for patients with advanced cancer 15. The company is also emphasizing the development and potential approval of its Shield blood test for colorectal cancer screening, which has received a strong recommendation from an FDA advisory committee 16. Despite these advancements, Guardant is not expected to generate positive cash flows until 2028, as it navigates payer coverage and guideline inclusion uncertainties 17.
14: Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance View Source15: Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer View Source16: Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024 Business Wire Jul 24, 2024 8:05pm Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance Business Wire Jul 23, 2024 12:05pm Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors Business Wire Jul 18, 2024 9:00pm Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer Business Wire Jun 4, 2024 12:05pm Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials Business Wire Jun 3, 2024 1:18pm Guardant Health Named to TIME100 Most Influential Companies Business Wire May 31, 2024 12:05pm Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening Business Wire May 30, 2024 12:05pm Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test Global News Select May 23, 2024 11:40pm FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option Business Wire May 23, 2024 11:03pm Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening Business Wire May 23, 2024 11:05am Guardant Health to Participate in Upcoming Investor Conferences Business Wire May 22, 2024 8:05pm Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications Business Wire May 21, 2024 12:05pm Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire May 17, 2024 12:05pm Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week Business Wire May 16, 2024 12:05pm Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Business Wire May 9, 2024 8:05pm Guardant Health to Participate in Upcoming Investor Conferences Business Wire May 7, 2024 8:05pm Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone Business Wire May 7, 2024 12:00pm Guardant Health shares slide as colon cancer test is set for FDA advisory committee review MarketWatch Dec 20, 2023 1:42pm View Source17: Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer, or CRC. It launched Reveal, its MRD test, for CRC in 2021 and a lab-developed test, or LDT, version of Shield, its CRC screening test, in 2022. Although these are promising markets with multi-billion-dollar revenue potential, it is still the early days, and considerable uncertainty surrounds the details of payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028, or two years after Shield’s potential inclusion in the U.S. Preventive Services Task Force, or USPSTF, guidelines in 2026. View Source